Form 4: Revolution Medicines CFO Executes Pre-Planned Stock Sales
Insider Transaction Report
Revolution Medicines' Chief Financial Officer, Jack Anders, executed pre-planned transactions involving the exercise of stock options and subsequent sale of common stock.
Summary
- Jack Anders, Chief Financial Officer of Revolution Medicines, Inc. (RVMD), reported transactions under a Rule 10b5-1 trading plan adopted on December 16, 2024.
- On September 2, 2025, Mr. Anders exercised options to acquire 2,814 shares at $2.68 and 1,948 shares at $4.73, totaling 4,762 shares.
- Concurrently on September 2, 2025, he sold 4,762 shares of common stock at a weighted average price of $40.0168.
- On September 3, 2025, Mr. Anders exercised options to acquire 3,189 shares at $4.73 and 2,049 shares at $17, totaling 5,238 shares.
- Concurrently on September 3, 2025, he sold 5,238 shares of common stock at a weighted average price of $40.1742.
- Following these transactions, Mr. Anders beneficially owns 113,314 shares of common stock, which includes 54,213 Restricted Stock Units (RSUs).
Sentiment
Score: 5
Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling. It represents a routine liquidity event for the executive.
Positives
- The exercise of stock options at significantly lower prices ($2.68, $4.73, $17) compared to the sale prices (approximately $40) indicates a substantial gain for the reporting person.
- The transactions were executed under a pre-arranged 10b5-1 trading plan, demonstrating a structured approach to managing equity holdings and reducing concerns about opportunistic insider trading.
Negatives
- The sale of 10,000 shares of common stock by a Chief Financial Officer, even under a 10b5-1 plan, represents a reduction in direct equity exposure to the company.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of insider transactions and does not provide specific insights into broader industry trends or competitive landscape within the biotechnology sector. Such transactions are common for executives managing their personal equity portfolios.
Stakeholder Impact
- Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, could be interpreted by some as a lack of confidence, though the pre-planned nature generally reduces this concern. The net effect on the total outstanding shares is negligible from these specific transactions.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 2022-08-16 | Date exercisable for a stock option with an expiration date of 09/26/2028. |
| 2023-08-09 | Date exercisable for stock options with an expiration date of 08/08/2029. |
| 2024-02-12 | Date exercisable for a stock option with an expiration date of 02/11/2030. |
| 2024-12-16 | Date the 10b5-1 trading plan was adopted by the Reporting Person. |
| 2025-09-02 | Transaction date for the exercise of 4,762 stock options and the sale of 4,762 common shares. |
| 2025-09-03 | Transaction date for the exercise of 5,238 stock options and the sale of 5,238 common shares. |
| 2025-09-04 | Signature date of the reporting person for the Form 4 filing. |
| 2028-09-26 | Expiration date for a stock option exercised on 09/02/2025. |
| 2029-08-08 | Expiration date for stock options exercised on 09/02/2025 and 09/03/2025. |
| 2030-02-11 | Expiration date for a stock option exercised on 09/03/2025. |
Keywords
Revolution Medicines, RVMD, Jack Anders, CFO, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Equity Sales, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.